Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KAINOS LaboratoriesTSE:4556 40 Net Current Asset Value is 円950.87 as of Mar. 2026, which is 100% below its 10-year median of 2.38. GuruFocus rates TSE:4556 with a GF Score™ of 40/100 and a GF Value™ of 円1,282.77 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 569 Medical Devices & Instruments companies, KAINOS Laboratories ranks better than 76.27% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
KAINOS Laboratories's net current asset value per share for the quarter that ended in Mar. 2026 was 円950.87.
The historical rank and industry rank for KAINOS Laboratories's Net Current Asset Value or its related term are showing as below:
TSE:4556'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.39 Med: 2.38 Max: 5.97
Current: 2.39
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of KAINOS Laboratories was 5.97. The lowest was 1.39. And the median was 2.38.
TSE:4556's Price-to-Net-Current-Asset-Value is ranked better than 76.27% of 569
companies
in the Medical Devices & Instruments industry
Industry Median: 4.83
vs TSE:4556: 2.39
KAINOS Laboratories (TSE:4556) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
KAINOS Laboratories Net Current Asset Value Related Terms
KAINOS Laboratories Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for KAINOS Laboratories's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4556 vs ISRG, BDX, MDLN: Net Current Asset Value Comparison
For the Medical Instruments & Supplies subindustry, KAINOS Laboratories's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KAINOS Laboratories Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KAINOS Laboratories's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where KAINOS Laboratories's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of 円950.87 mean?
KAINOS Laboratories (TSE:4556) has a Net Current Asset Value of 円950.87 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on KAINOS Laboratories and its competitors. This is 39853% above median its historical median of 2.38. Over the past decade, KAINOS Laboratories' Net Current Asset Value has ranged from 1.39 to 5.97. According to the industry distribution chart, KAINOS Laboratories ranks #135 out of 569 companies in the Medical Devices & Instruments industry, placing it in the top 23.7%.
Is KAINOS Laboratories' Net Current Asset Value too high?
KAINOS Laboratories' current Net Current Asset Value of 円950.87 is 39853% above median its 10-year median of 2.38. Over the past 10 years, this metric has ranged from a low of 1.39 to a high of 5.97. Based on the distribution chart, KAINOS Laboratories ranks #135 out of 569 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, KAINOS Laboratories has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does KAINOS Laboratories' Net Current Asset Value compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, KAINOS Laboratories ranks #135 out of 569 companies for Net Current Asset Value. This places KAINOS Laboratories in the top 24% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 4.83. Historically, KAINOS Laboratories' own Net Current Asset Value has ranged from 1.39 to 5.97 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.83, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on KAINOS Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KAINOS Laboratories's current Net Current Asset Value is 円950.87, which is 39853% above median its own 10-year median of 2.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KAINOS Laboratories stock overvalued right now?
Based on GuruFocus' analysis, KAINOS Laboratories (TSE:4556) is currently considered Significantly Overvalued. The stock's GF Value™ is 円1,282.77, compared to a current price of 円2,268.00 — trading 76.8% above its estimated fair value. The current Net Current Asset Value is 円950.87, which is 39853% above median its 10-year median of 2.38. KAINOS Laboratories' overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For KAINOS Laboratories (TSE:4556), the current Net Current Asset Value is 円950.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KAINOS Laboratories (TSE:4556) Overvalued in 2026?
Based on GuruFocus' analysis, KAINOS Laboratories stock appears to be overvalued.
The current stock price of 円2,268.00 is trading 76.8% above its estimated GF Value™ of 円1,282.77.
GuruFocus considers KAINOS Laboratories to be Significantly Overvalued.
Key valuation signals for TSE:4556:
Net Current Asset Value: 円950.87 (39853% above median its 10-year median of 2.38)
GF Value™: 円1,282.77 vs. price of 円2,268.00 (76.8% above fair value)
No single metric tells the full story. See the TSE:4556 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KAINOS Laboratories Inc is focused on the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products. It also manufactures, sells, and exports/imports physicochemical measuring equipment for medical use.
40GF Score
Get the complete analysis for TSE:4556
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4556 has been successfully added to your 
